Alvotech To Be The Global Frontrunner For Stelara Biosimilars Following Approval Of Selarsdi In US
Pharmaceuticals / United States / Fri 19 Apr, 2024
Key View
- Alvotech will be the global frontrunner for ustekinumab biosimilars following its latest approval of Selarsdi in the US.
- Johnson & Johnson will delay new entrants with ongoing patent litigation settlements, although the 2024 and 2025 patent cliffs are quickly approaching.
- Stelara revenue will be impacted immediately following